1	Investigating antibody reactivity to the intestinal microbiome in severe
2	myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
3	
4	Katharine A. Seton ¹ , Marianne Defernez ¹ , Andrea Telatin ¹ , Sumeet K. Tiwari ¹ ,
5	George M. Savva ¹ , Antonietta Hayhoe ¹ , Alistair Noble ³ , Ana Carvalho ⁴ , Steve
6	James ¹ , Amolak Bansal ⁵ , Thomas Wileman ^{1,2} and Simon R. Carding ^{1,2}
7	
8	¹ Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK
9	² Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK
10	³ The Pirbright Institute, Woking, GU24 0NF, UK
11 12	⁴ Experimental Arthritis Treatment Centre for Children, University of Liverpool, Liverpool, L12 2AP
13	⁵ Spire St Anthony's Hospital, Surrey, SM3 9DW, UK
14	
15	
16	Corresponding author:
17	Prof. Simon R. Carding
18	Food, Microbiome and Health Research Programme
19	Quadram Institute Bioscience
20	Norwich Research Park
21	Norwich, NR4 7UQ
22	U.K.
23	(e) <u>simon.carding@quadram.ac.uk</u>

24 Abstract

25 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystemic disease of 26 unknown aetiology that is characterised by disabling chronic fatigue and involves both the 27 immune and gastrointestinal (GI) systems. Patients display alterations in GI microbiome with 28 a significant proportion experiencing GI discomfort and pain and elevated blood biomarkers for altered intestinal permeability compared with healthy individuals. To investigate a 29 30 possible GI origin of ME/CFS we designed a feasibility study to test the hypothesis that 31 ME/CFS pathogenesis is a consequence of increased intestinal permeability that results in 32 microbial translocation and a breakdown in immune tolerance leading to generation of 33 antibodies reactive to indigenous intestinal microbes. Secretory IgA and serum IgG levels 34 and reactivity to intestinal microbes were assessed in five pairs of severe ME/CFS patients 35 and matched same-household healthy controls. For profiling serum IgG we developed IgG-36 Seq which combines flow-cytometry based bacterial cell sorting and metagenomics to detect 37 mucosal IgG reactivity to the microbiome. We uncovered evidence for immune dysfunction 38 in severe ME/CFS patients that was characterised by reduced capacity and reactivity of serum 39 IgG to stool microbes, irrespective of their source. This study provides the rationale for 40 additional studies in larger cohorts of ME/CFS patients to further explore immunemicrobiome interactions. 41

42

Keywords: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), antibodies,
immunoglobulin G, immunoglobulin A, microbiome, autologous, heterologous, immune tolerance,
leaky gut.

46 **Introduction:**

47 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterised by disabling fatigue and autonomic, muscular, cognitive, neurological and immune symptoms that leave 48 patients unable to undertake their pre-morbid work, education, exercise and social activities¹. 49 A quarter of diagnosed patients are house- or bedbound² and less than 5% ever recover their 50 pre-morbid activity levels³. A meta-analysis based on 45 studies estimated an average 51 population prevalence of 0.68% (95%CI = 0.48 to 0.97)⁴. However, these estimates vary 52 considerably by population and case definition⁴. The prevalence is anticipated to rise 53 following the COVID-19 pandemic as 45.2% of long COVID patients fulfil ME/CFS 54 diagnostic criteria⁵. The most common trigger of ME/CFS is an infection, while other 55 reported triggers include physical or mental trauma and toxin exposure³. 56

57 Several factors have been implicated in ME/CFS pathogenesis involving the immune 58 (autoimmunity, inflammation and chronic infection), gastrointestinal (GI), neurological, endocrine and metabolic systems⁶. Between 38 and 92% of ME/CFS patients report co-59 morbid GI disturbances such as IBS^{3,7-9} and 35% of patients take medication for GI 60 disturbances including pro- and prebiotics, digestive enzymes and sodium bicarbonate³. The 61 high co-occurrence of ME/CFS and IBS suggests possible involvement of the intestinal 62 63 microbiome. Consistent with this possibility several studies have reported changes in the 64 community structure of the stool microbiome of ME/CFS patients exemplified by reduced diversity⁸ and decreased abundance of short-chain fatty acid producing bacterial species⁸⁻¹². 65 ME/CFS patients may also have elevated biomarkers associated with increased intestinal 66 permeability^{8,13,14}. Intestinal inflammation and increased permeability can compromise 67 68 immune and microbial tolerance (defined as a state of hypo responsiveness to autologous intestinal microbes)¹⁵ leading to hyperreactivity and serum antibody production to 69 autologous intestinal microbes¹⁶; this can pre-stage autoimmune disease¹⁷. Of note, ME/CFS 70

patients displaying increased intestinal permeability have a higher incidence of serotonin
 autoimmunity¹⁸.

Based upon these observations we hypothesised that ME/CFS pathology is a 73 consequence of the breakdown in immune tolerance resulting from the increased intestinal 74 75 permeability and microbial translocation that leads to generation of antibodies reactive to autologous intestinal microbes. In support of this proposal, a previous study found that, 76 77 compared with healthy controls, ME/CFS patients had abnormally high levels of IgA and IgM produced in response to a panel of seven gram-negative enterobacteria¹³. However, this 78 79 small panel of microbes does not reflect the complexity of the intestinal microbiota which comprises 300-500 bacterial species as well as viruses, archaea and fungi¹⁹. In addition, IgM 80 antibodies have low specificity for antigens²⁰ and IgA is primarily produced at mucosal 81 sites²¹. Serum IgG reactivity to the microbiome in ME/CFS patients has recently been 82 83 investigated using phage immunoprecipitation sequencing (PhIP-Seq) to screen IgG reactivity to 244,000 bacterial and viral epitopes²². This study is, however, restricted to 84 identifying antibody reactivity to peptide antigens and cannot detect reactivity to the 85 86 immunogenic glycoproteins and lipoproteins that decorate the outer membrane and surface of bacterial cells, viruses and fungi²³. Furthermore, none of the approaches used to date provide 87 88 information on whether immune tolerance to indigenous intestinal microbes is lost in 89 ME/CFS.

To begin to address this important question and assess the systemic humoral immune response to indigenous microbes we adapted 'IgA-Seq', a method that combines flowcytometry-based bacterial cell sorting and 16S rRNA sequencing to detect mucosal IgA reactivity to the microbiome²⁴, to characterise serum IgG reactivity to the microbiome; we refer to this new method as IgG-Seq. To evaluate the IgG-Seq protocol, we designed a feasibility study with a small cohort of severe ME/CFS patients and healthy controls from the

same households. The difficulty in accessing housebound or bedbound patients is a major
obstacle to understanding the pathophysiology and aetiology of ME/CFS and is why only
0.5% of ME/CFS research is undertaken in severely affected patients². One aim of this study,
therefore, was to assess the feasibility of, and barriers to, including severe ME/CFS patients
in research involving the collection of biological samples.

101

102 **Results:**

103 *Recruiting severe ME/CFS patients and same household controls*

104 Study participants were recruited from the CFS clinic at Epsom and St Helier University 105 Hospitals (ESTH), Carshalton, UK and the ME/CFS service at East Coast Community 106 Healthcare Centre, Lowestoft, UK which together had 3,812 registered patients. Recruitment 107 began in October 2017, with the intention of recruiting ten severe house- or bedbound 108 ME/CFS patients and ceased in April 2020 due to the COVID-19 pandemic. Thirty-six 109 patients were invited to the study with a response rate of 58.3% (Supplementary Fig. S1). Of 110 those who responded, 42.9% were ineligible due to either the absence of a household control 111 (n = 4), failure to meet other inclusion criteria (n = 4) or were unable to provide written 112 informed consent (n = 1). Of the 12 eligible pairs of participants, six provided informed 113 consent. The consenting appointments for the other six eligible participants were delayed 114 either due to patients rescheduling their appointments when feeling unwell, or the non-115 availability of phlebotomists to attend home visits. Consequently, consenting appointments 116 were delayed by up to 12 months for participants, by which point three patients either saw 117 their health further deteriorate preventing them from participating in the study, or acquired an 118 additional health complication that excluded them from the study. We received no further 119 communication from the remaining three pairs.

120 Study population characteristics

121 Samples were collected from five pairs of participants; one pair consented immediately prior 122 to the COVID-19 pandemic which prevented us from obtaining their samples (Table 1). The 123 recruited patients comprised four females and one male (mean age 33.8 years; standard 124 deviation (SD) 13.8). There was clinical heterogeneity amongst patients, with variation in the 125 age at which ME/CFS onset occurred, length of illness and symptom severity. Three patients 126 reported ME/CFS onset following a viral infection, one following vaccination and one 127 following surgery. IBS was reported in all patients but in none of their matched household 128 controls. Same household healthy controls included four males and one female (mean age 129 40.4 years; SD 16.7) who were the carers and spouse (n = 3), parent (n = 1) or sibling (n = 1)130 of the patients.

131 Stool consistency does not separate severe ME/CFS patients with IBS from matched 132 household controls without IBS

133 Despite all ME/CFS patients, and no household controls, reporting IBS there was no evidence 134 for a difference in consistency of the collected stool samples between patients and controls, 135 as measured by the Bristol stool form scale (BSFS) or by water content (Fig. 1A and 1B). 136 Three controls had abnormally loose stools (BSFS 5-7) indicative of diarrhoea and one 137 control had an abnormally hard stool (BSFS 2) indicative of constipation. In contrast, two 138 patients had stool samples defined as having a healthy consistency (BSFS 3-4), one patient 139 had an abnormally loose stool (BSFS 5) and two patients had abnormally hard stools (BSFS 140 1-2).

141 Assessment of secretory IgA in stool

The concentrations of microbe bound IgA1/2 (Fig. 2A) and free IgA1/2 (Fig. 2B) were measured by ELISA with no evidence of a significant difference between severe ME/CFS

patients and their matched household controls. Flow cytometry was used to determine the distribution of IgA coating on stool microbes (Fig. 3A and 3B). When comparing the proportion of stool microbes coated by IgA there was no evidence of any differences between patients and matched controls (Fig. 3C). Based on the microbial load of stool samples (Supplementary Fig. S2) the relative quantification of IgA bound microbes was converted to absolute values which again revealed no evidence of differences between patients and matched controls in the quantity of IgA coated microbes within stool samples (Fig. 3D).

151 Severe ME/CFS patients have a reduced serum IgG immune response to stool microbes

152 To determine whether immune tolerance to intestinal microbes was altered in severe ME/CFS 153 patients the level of serum IgG antibodies bound to both their own (autologous) stool 154 microbes and to non-self (heterologous) stool microbes from other individuals were measured 155 in patients and their matched household controls (Fig. 4A). Four patients had lower serum 156 IgG reactivity to indigenous stool microbes than their matched household controls (p =157 0.07322) and all patients had lower serum IgG reactivity to foreign stool microbes than their matched household controls (p = 0.006334) (Fig. 4B). Furthermore, there was evidence for 158 159 controls having higher serum IgG reactivity to heterologous (patient) stool microbes than 160 serum IgG reactivity to autologous stool microbes (p = 0.0317). In contrast, for patients there 161 was no evidence for a difference in serum IgG reactivity to autologous and heterologous 162 (control) stool microbes (p = 0.3619). In addition, serum IgG reactivity to patients 163 (heterologous) stool microbes in control individuals was higher than serum IgG reactivity to 164 autologous stool microbes in patients (p = 0.003751). A paired t-test of the averaged IgG 165 levels to indigenous and foreign stool microbes within individuals suggests that patients had a 166 lower IgG reactivity to stool microbes than controls irrespective of the source of the microbes 167 (p = 0.0185). Of note, the reduced levels of patient IgG antibodies to indigenous and foreign 168 stool microbes were not due to lower levels of serum IgG in patients (Fig. 4C).

169 The proportion of microbes bound by serum IgG is high in both patients and controls

We next sought to determine how much of the stool microbiome was recognised by serum IgG by measuring the proportion of indigenous stool microbes coated by serum IgG (Fig. 5A and 6B). There was no evidence for any differences in the proportion of stool microbes coated by IgG ('IgG positive') in severe ME/CFS patients compared with controls (Fig. 5C).

174 Characterising the stool microbiome

Using whole metagenome shotgun sequencing the microbial composition of SYBR Green⁺ ('all') stool microbes isolated by fluorescent activated cell sorting (FACS) was determined (Supplementary Fig. S3). The average number of 'all' microbes collected by FACS was 1.47 million. Taxa with a relative abundance greater than 1 x 10^{-6} were included in downstream analyses and comparisons made at the genus and species level.

At the genus level 275 taxa were detected. The 15 most abundant genera across all ME/CFS and matched household control samples (n = 10) were *Bacteroides* (10.4%), *Phocaeicola* (10.1%), *Clostridioides* (9.5%), *Lysobacter* (9.4%), *Faecalibacterium* (8.6%), *Blautia* (7.1%), *Roseburia* (5.8%), *Anaerostipes* (5.5%), *Akkermansia* (4.4%), *Campylobacter* (2.9%), *Agrobacterium* (2.6%), *Methanobrevibacter* (1.9%), *Bifidobacterium* (1.9%) *Anaerobutyricum* (1.5%) and *Streptococcus* (1.3%) (Supplementary Fig. S3A).

At the species level 705 taxa were detected. The 15 most abundant species across all ME/CFS and matched household control samples (n = 10) were *Clostridioides difficile* (9.5%), *Lysobacter enzymogenes* (9.4%), *Faecalibacterium prausnitzii* (8.6%), *Phocaeicola dorei* (6.4%), *Blautia* sp. SC05B48 (6.3%), *Anaerostipes hadrus* (5.4%), *Roseburia intestinalis* (4.5%), *Akkermansia muciniphila* (4.3%), *Bacteroides uniformis* (3.7%), *Phocaeicola vulgatus* (3.6%), *Agrobacterium tumefaciens* (2.5%), *Methanobrevibacter* smithii (1.8%), Bacteroides cellulosilyticus (1.6%), Anaerobutyricum hallii (1.5%) and
Campylobacter jejuni (1.5%) (Supplementary Fig. S3C).

Using three measures of intra-sample diversity, the Shannon index, inverse Simpson index and observed richness, there was no evidence for differences in any of the alpha diversity measures between severe ME/CFS patients and matched household controls at the species level (Supplementary Fig. 4A).

198 Due to the large variation in microbial load in stool samples from severe ME/CFS patients (6.3 x 10^{10} cells/gram to 2.6 x 10^{11} cells/gram) and controls (1.2 x 10^{11} cells/gram to 199 200 2.0 x 10^{11} cells/gram) (Supplementary Fig. S2), converting relative abundances to absolute 201 abundances increased the heterogeneity amongst samples at both the genus and species levels 202 (Supplementary Fig. S3B and S2D). However, analysis of beta diversity using Bray-Curtis 203 dissimilarity identified subtle changes in both relative microbiome profiles (RMP) and 204 quantitative microbiome profiles (OMP). Samples from patients in pairs three, four and five 205 were most dissimilar to the other samples while samples from patients in pairs one and two 206 clustering together with their matched household controls (Supplementary Fig. S4B).

207 Functional differences in the microbiome of patients and controls were determined by 208 comparing the abundance of gene families in the 'all' fraction. A total of 464,263 gene 209 families were detected in all participants above the threshold. A further filtering step removed gene families below the threshold in more than seven samples, leaving 84,888 gene families 210 211 for evaluation. PCA was used to reduce the number of variables by defining principal 212 components (PC) that highlighted the largest sources of variation amongst the samples. PC4 213 identified 11% of variation in functional genes families amongst samples that were 214 attributable to disease status (Supplementary Fig. S5).

215 IgG-Seq identifies antimicrobial signatures unique to each participant

216 Next, IgG-Seq was used to characterise the indigenous gut microbes bound by serum IgG in 217 severe ME/CFS patients and matched household controls. Briefly, 'IgG positive' and 'IgG 218 negative' microbes were isolated by FACS from bulk stool samples and processed for 219 shotgun metagenomic sequencing to identify taxa preferentially bound by serum IgG (Fig. 6A and 6B). The mean number of 'IgG positive' microbes collected by FACS was 1.05×10^6 . 220 The mean number of 'IgG negative' microbes isolated by FACS was 1.30×10^6 . Taxa with a 221 relative abundance greater than 1×10^{-5} in the 'all' fraction were included in the 'IgG 222 positive' and 'IgG negative' fractions for downstream analyses. Taxonomic comparisons 223 224 were made at the species level.

225 Observed richness scores were applied to rarefied reads to determine the number of 226 microbial species with serum IgG reactivity (Fig. 6C). All participants had more than 200 227 species in the 'IgG positive' fraction with a high number of species also identified in the 'IgG 228 negative' fraction. Both patients and controls had a higher mean number of species in their 229 'IgG negative' fraction than their 'IgG positive' fraction (365 vs 339 in patients and 358 vs 230 322 in controls). However, most participants had a small number of species (<30) exclusively in the 'IgG negative' fraction at a relative abundance $>1 \times 10^{-5}$, except for the patient from 231 232 pair three who had 107 species exclusively in their 'IgG negative' fraction (Table 2). In 233 addition, this patient also had a smaller proportion of species recognised by IgG compared 234 with all other participants (Table 2).

Next, we assessed the similarity/difference between 'IgG positive' and 'IgG negative' fractions in patients and controls using the Bray-Curtis index and visualising distances using an NMDS plot (Fig. 6D). 'IgG positive' and 'IgG negative' fractions from the same participant shared the greatest similarity. No clustering was seen for either fraction in patients or controls. The 'IgG positive' and 'IgG negative' fractions from patients in pairs three and five were most dissimilar to the other samples.

Using the probability ratio developed by Jackson et al., (2021)²⁵ we scored IgG 241 242 binding by directly measuring the likelihood of a species being bound by IgG. Positive IgG 243 probability ratios indicate that a species is more likely to be coated with IgG and reside in the 244 'IgG positive' fraction. Conversely, negative IgG probability ratios indicate that a species is 245 more likely to be uncoated and reside in the 'IgG negative' fraction. Probability ratios are not 246 influenced by the relative abundance of a species within the 'all' fraction and therefore 247 measure the quantity of IgG produced against a given species. Of the 423 species detected at a relative abundance greater than 10⁻⁵, 101 species were detected in every participant and 248 249 therefore used in downstream analysis. It is worth noting that despite detecting species falling 250 into the bacteria, fungi, archaea and virus kingdoms, only bacterial species were detected in 251 every participant and consequently used in downstream analysis. Notably, owing to the way 252 in which probability ratios are calculated they tend to be similar across species within 253 participants, with some having consistently lower estimates across all species than others, 254 driven by their overall IgG probability ratio. Probability ratio scores varied amongst species 255 and participants. Each participant had a unique combination of probability ratio scores for 256 different species (Fig. 7). We were unable to meaningfully test for differences in probability 257 ratio scores between patients and controls for individual species due to the small sample size 258 and lack of power to detect significant changes.

Finally, we analysed the function of the microbial communities within the 'IgG positive' and 'IgG negative' fractions by analysing the likelihood of a gene family being present in a microbe bound by IgG. IgG probability ratios were calculated for the 1724 gene families that were detected in all participants above the threshold. Using a PCA plot to assess how the ten samples varied with regards to the likelihood of certain gene families being present in microbes bound by IgG (Supplementary Fig. S6), a separation between severe

ME/CFS patients and controls from four households was observed (PC2), corresponding to 13% of explained variance.

267

268 **Discussion:**

This feasibility study highlights the logistical challenges of including severe, house- or bedbound ME/CFS patients in research studies and collecting biological samples. Contrary to our initial hypothesis, our findings from a small cohort of patients and controls suggests that severe ME/CFS patients may have a reduced serum IgG immune response to stool microbes.

273 Lessons learnt for the inclusion of severe ME/CFS patients in biomedical research

274 Despite their significant disability severe ME/CFS patients were enthusiastic and eager to 275 participate in our study with a 58% response rate. However, severe ME/CFS often coincided 276 with additional illness complications that excluded these individuals from the study, 277 hindering recruitment. We also found that symptom severity of house- or bedbound ME/CFS 278 patients fluctuated, making it difficult to arrange home study visits. The wide geographical 279 distribution of participants' homes (30 - 140 miles from the research institute) restricted 280 sample collection with a minimum of two hours required for sample collection and 281 transportation to the laboratory.

We recruited controls from the same household as the patient to account for environmental confounders of microbiome analyses such as living conditions and diet^{26,27}. Previous studies have shown that inclusion of same household controls enables identification of ME/CFS disease-specific microbiome changes²⁸. However, the requirement for a matched healthy household control impacted on patient recruitment. Amongst patients not meeting the study eligibility criteria, 44% were excluded due to being unable to identify a matched household control. Considering that household controls were typically carers and parents or

289 spouses of the patient, it was not possible to match age and gender of patients and controls, both of which are confounding variables for immunological^{29,30} and microbiome studies³¹. 290 Other confounders potentially discordant amongst patients and controls were BMI, exercise 291 292 and medications. Our finding of a sparse clustering between results from severe ME/CFS 293 patients and matched household controls suggests that these and perhaps other confounding 294 variables had an influence on immune response to the intestinal microbiome. Future studies 295 should consider including and accounting for as many of these confounding variables in 296 analysis as possible.

297 Severe ME/CFS patients have serum IgG hyporeactivity to stool microbes

298 The hypothesis guiding our study was that ME/CFS patients have increased intestinal 299 permeability due to an altered microbiome, which results in translocation of intestinal 300 microbes into the circulation, triggering an immune response. Despite the low study sample 301 size, we found evidence that severe ME/CFS patients in fact have lower serum IgG levels 302 reactive to stool microbes than their matched household controls. This appears to be a 303 property of the patients' immune responses, rather than their microbiome which structurally 304 and functionally closely resembled that of their matched controls. Our findings mirror the 305 findings from pioneering studies investigating immune reactivity to faecal microbes in IBD 306 patients which demonstrated that healthy controls have higher serum IgG reactive to heterologous stool microbes than to autologous stool microbes¹⁵. In our study heterologous 307 308 reactivity was measured using samples from individuals living in the same household which 309 are known to display greater similarity to patients' microbiomes than individuals living in different households³². This should increase confidence in identifying microbes that 310 311 distinguish the microbiome of patients from controls as being a property of the disease. 312 Despite this advantage there were no differences in alpha diversity measures between severe 313 ME/CFS patients and matched household controls at the genus or species level. Instead, our

314 findings provide initial evidence for immune dysfunction in ME patients manifesting as a 315 reduced capacity and reactivity of serum IgG to stool microbes irrespective of their source. Previous studies have described IgG immunodeficiencies in ME³³ which could explain why 316 317 we found reduced levels of serum IgG binding to stool microbes in severe ME/CFS patients. 318 However, there was no evidence of IgG immunodeficiencies in our severe ME/CFS patient 319 cohort. Instead, it may be attributable to IgG antibody repertoires and a less diverse repertoire 320 of antibodies directed at intestinal microbes. The loss of antibody diversity occurs naturally 321 during ageing and is a defining feature of immune senescence and declining immune function in later life³⁴. The possibility of premature or accelerated immunosenescence should be a 322 323 focus of future studies, particularly as it relates to effector immune cells whose functionality is compromised in ME patients, as previously described for NK cells³⁵, and here for B cells. 324 325 An additional possibility relates to immune hibernation in ME/CFS patients which produces a hypometabolic state³⁶ that may limit lymphocyte responsiveness to foreign antigens and 326 increased tolerance to bacterial endotoxins³⁷. 327

328 Limitations of the study in addressing the study hypothesis

The severe ME/CFS patients recruited to this pilot study had comorbid IBS, whereas household controls were free of any GI complaints. IBS comorbidity is a confounding variable in ME/CFS microbiome studies as defined microbiome profiles have been described that discriminate between patients with and without IBS comorbidity⁹. To establish whether the results found in this pilot study of severe ME patients are disease specific future studies should compare severe ME/CFS patients with and without comorbid IBS and compare severe ME/CFS patients with comorbid IBS to IBS patients.

We were unable to confirm the presence of increased intestinal permeability within the severe ME/CFS patient cohort. Based upon previous studies most ME patients (~67%)

will have increased intestinal permeability compared with healthy controls¹³. An intact intestinal barrier in the severe ME/CFS patients recruited to this study might explain why they did not have increased IgG reactivity to autologous stool bacteria compared with their matched healthy household controls. It has been shown that levels of IgG reactive to autologous stool bacteria are elevated in other diseases associated with increased intestinal permeability such as Crohn's disease¹⁶. Future studies should seek to establish the integrity of the intestinal barrier in severe ME/CFS patients.

The IgG-Seq protocol used in this research identified serum IgG produced in response to bacteria and fungi. Whilst excluding reactivity to other constituents of the intestinal microbiome in the current study, the method can be adapted to detect IgG reactivity to viruses and archaea that can then be identified and isolated using FACS.

349 *Conclusion*

Severe ME patients have historically been excluded from research studies. This pilot study demonstrates the feasibility and challenges associated with including this important and growing population of ME patients in research. In providing evidence of immune dysfunction in severe ME/CFS patients, expressed as hyporesponsive serum IgG responses to intestinal microbes, this study also provides the theoretical and methodological basis and rationale for undertaking more detailed immune function studies in larger cohorts of ME patients.

356

357 Patients and Methods

358 Participant recruitment

Ten volunteers were enrolled onto this study between 2018 and 2019: Five severe ME/CFS patients and, as controls, five healthy individuals that were the patients' carers and living in

361 the same household. Severe ME/CFS participants were recruited by the tertiary referral 362 centres Epsom and St Helier University Hospitals (ESTH) CFS Service, Carshalton, UK, and 363 the East Coast Community Healthcare Centre (ECCHC) ME/CFS service, Lowestoft, UK. 364 All severe ME/CFS patients had a confirmed diagnosis of ME/CFS based on a hybrid of the NICE 2007 guidelines³⁸ and the CDC-1994 criteria³⁹ and defined as experiencing at least four 365 366 of the following symptoms for a minimum of 4 months; cognitive difficulties, muscle pain, 367 multi-joint pain, new headaches, recurrent sore throats, cervical/axillary lymphadenopathy, 368 unrefreshing sleep and post exertional malaise. Severity was based on being unable to 369 undertake activities associated with daily living, wheelchair dependency for mobility and 370 being house- or bedbound and requiring aid for washing, using the toilet and eating. All 371 patients were asked to complete the Chalder fatigue questionnaire, shortened medical 372 outcomes study 36-item short form health survey (SF-36), hospital anxiety and depression 373 scale (HADS), a self-efficacy questionnaire, visual analogue pain rating scale and the 374 Epworth sleepiness scale. Matched household controls were defined as individuals who were 375 living with or caring for the severe ME/CFS patient. Matched household controls were 376 excluded if they had a long-term medical condition, in particular gastrointestinal conditions, 377 autoimmune diseases, anxiety, or depression; or were receiving immunomodulatory drugs, 378 statins, beta blockers or steroids. Participants consuming antibiotics or probiotic capsules 379 within the 6 weeks prior to sample collection were excluded.

The study was performed in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice (ICH GCP) Guideline, and in compliance with national law. The research was approved by the NHS Health Research Authority London Hampstead Research Ethics Committee (REC 17/LO/1102, IRAS ID 218545). This study was registered on the clinicaltrials.gov database (NCT03254823). All participants provided fully informed written consent. The collection,

storage and use of human tissue samples was carried out within the terms of the Human
Tissue Act 2004 (Human Tissue Authority).

388 Sample collection and processing

389 Fresh stool and blood samples were collected from each participant within a 24 h window 390 during a home visit. Twenty millilitres of blood were collected in serum separator tubes (BD 391 Vacutainer). Serum was separated from whole blood following the manufacturers protocol 392 and immediately stored at -80°C. Stool samples were collected immediately after defecation 393 in a Fecotainer® (AT Medical BV) with an Oxoid[™] AnaeroGen[™] compact sachet (Thermo 394 Scientific) to preserve anaerobic bacteria. The consistency and appearance of fresh stool samples was recorded using the Bristol stool form scale (BSFS)⁴⁰. Stool samples were stored 395 396 at 4°C for <24 h. Following homogenisation aliquots of the bulk homogenate and of 40% 397 stool microbial glycerol suspensions were stored at -80°C. Glycerol stocks were prepared by 398 diluting stool samples (10% w/v) with PBS, collecting the supernatant following 399 centrifugation at 300g for 5 min at 20°C and diluted 1:1 with 80% v/v glycerol.

400 Stool water content

401 Non-diluted aliquots of stool were weighed before and after freeze drying using the
402 ModulyoD freeze dryer (Thermo Electron Corp.) for 12 h. Water content was calculated
403 using the following equation.

$$\frac{(wet weight - dry weight)}{wet weight} \times 100$$

404 Stool microbial load

Non-diluted stool aliquots were thawed on ice and diluted (1% w/v) with PBS solution
containing 0.1% w/v BSA fraction V. Samples were homogenised using a KimbleTM
KontesTM Pellet PestleTM Cordless motor and filtered through a 70 µm cell strainer. Filtered

microbial suspensions were diluted 1:1600, 1:3200 and 1:6400; then 200µl of each dilution
were incubated with 10µl of 1:100 SYBRTM Green I nucleic acid gel stain (Thermofischer
Scientific) for 30 min. Microbial load was determined using the Guava® easyCyteTM 5HT
equipped with a 488 nm laser. Prior to sample acquisition the instrument was cleaned
following manufacturers' instructions and calibrated using the Guava® easyCheckTM kit.
Stool microbes (SYBR Green+ events) were enumerated using Guava® Suite Software v3.3.

414 Stool IgA concentration

415 Non-diluted stool aliquots were thawed on ice, diluted (10% w/v) with 0.2M NaHCO₃, pH 9.4 and homogenised using a KimbleTM KontesTM Pellet PestleTM Cordless motor. Samples 416 417 were centrifuged twice at 16,000g for 5 min at 20°C and after both rounds of centrifugation 418 the pellet and supernatant were separated. The supernatants were pooled and used to analyse 419 free secretory IgA (sIgA) by ELISA. The pellet was washed and resuspended to the original 420 volume and used to analyse microbe associated/bound sIgA by ELISA. All reactants except 421 for the blocking solution and wash buffers were added in volumes of 100 µl/well. All washes 422 were repeated three times with PBS and 0.05% TweenTM 20 unless otherwise stated. Nunc 423 MaxiSorpTM flat-bottom plates (Thermo Fisher Scientific) were coated for 16h at 4°C with 424 10-fold serial dilutions (1 to 1:1000000) of samples and with 2-fold serial dilutions (250-3.9 425 ng/ml) of a human colostrum IgA standard (Sigma), diluted with 0.2M NaHCO₃, pH 9.4. 426 Samples and standards were plated in duplicate. Plates were washed and then blocked for 3h 427 with 300µl/well of PBS, 0.05% Tween[™] 20, 2% BSA fraction V, 1% normal mouse serum 428 (Thermo Fisher Scientific). Plates were washed and then incubated with 1000 ng/ml biotin 429 conjugated mouse anti-human IgA1/IgA2 monoclonal antibody (Pharmingen) diluted in PBS, 430 0.05% TweenTM 20, 2% BSA fraction V, 1% normal mouse serum. After 1h of incubation at 431 20°C plates were washed and incubated with 1:80000 HRP-Conjugated Streptavidin (Thermo 432 Fisher Scientific) diluted in PBS, 0.05% Tween[™] 20, 2% BSA fraction V, 1% normal mouse

433	serum for 30 min at 20°C. Plates were washed six times and incubated with TMB high
434	sensitivity substrate solution (BioLegend® UK Ltd) for 5 min. The addition of 2N $\rm H_2SO_4$
435	stopped the reaction and absorbances were read at 450 nm. IgA sample values were
436	determined by reference to standard curves.

437 Serum IgG quantification

Total serum IgG was measured using the commercial Invitrogen ELISA kit (Thermo Fisher
Scientific). Samples were measured in duplicate.

440 Serum IgG levels to autologous and heterologous stool microbes

Glycerol stocks of stool microbes were thawed and washed three times with PBS at 8000g for
5 min at 20°C. The pellet was resuspended in 1ml PBS. Serial dilutions (2-fold) of stool
microbes in PBS were plated in duplicate in a 96-well flat bottom CorningTM CostarTM 9018
plate. Absorbances were read at 570 nm and stool microbes were resuspended to an optical
density of 0.05 with 0.1M NaHCO₃, pH 9.4.

446 Serum IgG reactivity to autologous ('self') or heterologous ('non-self', matched 447 patient or control) stool microbes was measured by ELISA. All washes were repeated three times with 200 µl/well PBS and 0.1% TweenTM 20 unless otherwise stated. Nunc 448 449 MaxiSorpTM flat-bottom plates (Thermo Fisher Scientific) were coated for 16h at 4°C with 450 100 µl/well of stool microbes. Plates were washed and then blocked for 3h at room temperature under agitation with PBS, 2% BSA fraction V, 1% normal goat serum (Sigma-451 452 Aldrich). Plates were incubated for 1 h at 20°C with 50 µl/well of complement inactivated 453 serum samples 2-fold serially diluted (1:80-1:320) in PBS, 2% BSA fraction V, 1% normal 454 goat serum. Plates were washed and incubated for 1h at room temperature under agitation 455 with 100 µl/well of 1:500 goat anti-human IgG H&L (HRP) (Abcam,) diluted in PBS, 2% 456 BSA fraction V, 1% normal goat serum. Plates were washed six times and incubated with

457	TMB high sensitivity substrate solution (BioLegend® UK Ltd) for 5 min at 20°C. The
458	addition of 0.16M H_2SO_4 stopped the reaction and absorbances were read at 450 nm. Results

459 were normalised by subtracting serum only absorbance readings from sample readings.

460 Microbial flow cytometry

461 Systemic IgG and faecal IgA binding to stool microbes was assessed by microbial flow 462 cytometry. All buffers were filter sterilised using a 0.22-um filter before use. Aliquots of 463 non-diluted stool samples were processed and the microbial concentration in each stool sample measured as described earlier. Microbes were resuspended to $2 \ge 10^6$ cells/ml in PBS 464 with 0.1% BSA. 500µl of complement inactivated serum was diluted 1:100 in PBS with 0.1% 465 BSA and incubated for 30 min at 20°C with 200 μ l of 1 x 10⁶ cells/ml of stool microbes. For 466 467 secretory IgA measurements stool microbes were not incubated with serum. Samples were washed in PBS with 0.1% BSA (5 min, 1.2×10^4 rpm) and microbes were resuspended to 1×10^4 rpm and microbes were resus 468 10⁶ cells/ml and incubated with 1:1000 SYBRTM Green I nucleic acid gel stain and 1:100 469 470 secondary conjugated antibodies (anti-human IgA-APC (Miltenyi Biotec) and anti-human 471 IgG-APC/Cy7 (BioLegend) or their respective isotype controls. Samples were fixed with 472 0.75% v/v paraformaldehyde. Acquisition of cellular events was performed using the BD 473 LSRFortessaTM (BD Biosciences) and analysed using FlowJoTM software. Frequencies of 474 antibody bound stool microbes were expressed as percentages. The percentage of Ig-bound 475 microbes was normalised by subtracting frequency of Ig-bound microbes measured using 476 isotype controls.

477 Metagenomic shotgun sequencing analysis of total gut microbiota and IgG-coated 478 microbes (IgG-Seq)

479 *Microbial cell sorting*

480 Non-diluted stool samples were processed and stained for IgG flow cytometry analysis as 481 described previously. Isotype controls were not used in microbial cell sorting. Microbes were diluted to 1×10^7 cells/ml and cell sorting achieved using the Sony SH800S cell sorter 482 483 equipped with four lasers: 488 nm, 405nm, 638nm and 651nm. Prior to sample acquisition 484 the instrument was cleaned and calibrated according to the manufacturer's instructions. Microbes (1×10^6) were collected from the following three fractions: 1) 'all' (SYBR⁺ 485 486 microbes), 2) 'IgG positive' (SYBR⁺IgG⁺), 3) 'IgG negative' (SYBR⁺IgG⁻). Fractions were 487 centrifuged and immediately stored at -20°C as dry pellets.

488 DNA extraction, processing and sequencing

489 DNA was extracted using the Gram-positive bacteria genomic DNA purification protocol 490 from the GeneJET DNA genomic DNA purification kit (Thermoscientific) with the following 491 modifications: 1) 0.52 kU/ml achromopeptidase was added to the lysis buffer and the 492 incubation time increased to 60 min; 2) incubation with lysis solution and proteinase K was 493 increased to 50 min. DNA was precipitated using 0.7X solid phase reversible immobilisation 494 bead clean-up with KAPA pure beads (Roche). Whole genome amplification was performed 495 using the REPLI-g advanced DNA single cell kit (QIAGEN). The quality and quantity of 496 amplified genomic DNA were determined using the Agilent Tapestation 4200 and the 497 Quanti-iTTM dsDNA high sensitivity assay kit (Thermo Fisher Scientific). A ready-to-load 498 pooled sequencing library was prepared by the in-house QIB sequencing service using the 499 Illumina DNA prep kit (Illumina, 20018704) and the KAP2G Robust PCR kit (Sigma), 500 followed by sequencing using 2 x 150 bp paired-end chemistry (PE150) on the Illumina 501 NovaSeq 6000 platform (Novogene Ltd., UK).

502 Paired-end sequencing reads were provided as FASTQ format. All raw sequencing 503 reads were pre-processed using tools retrieved from the BioConda repository⁴¹. SeqFu

 $(v1.8.5)^{42}$ was used to assess the quality of raw sequencing reads and those bases below 504 Phred quality score of 15 were removed using Fastp (v0.20.0)⁴³. Human genomic DNA 505 identified by Kraken244 against the Genome Reference Consortium Human Build 37 506 (GRCh37/hg19) database were removed. Taxonomic assignment of remaining sequencing 507 reads was done using Kraken2⁴⁴ against the 'PlusPF' database containing archaea, bacteria, 508 509 viral. human1, UniVec Core, plasma, Protozoa and Fungi 510 https://benlangmead.github.io/aws-indexes/k2. Abundance of reads at the species level was estimated using Bracken⁴⁵. Taxonomic read counts were converted to relative abundances by 511 512 total sum scaling to 1.

513 *Relative and quantitative microbiome profiling*

The 'all' fraction from microbial cell sorting was used for relative microbiome profiling (RMP) and quantitative microbiome profiling (QMP). The cut off threshold of $1 \ge 10^{-6}$ was applied to relative abundances and a pseudocount of $1 \ge 10^{-7}$ was added. The microbial load of each species was calculated on these modified relative abundances using the equation below.

absolute abundance
$$(cells/g)_{ij} = RA_{ij} \times total cell concentration (cells/g)_j$$

519 Analysing IgG binding of taxa

RMP data was used for IgG binding analysis with a cut off threshold of $1 \ge 10^{-5}$. In addition, for each participant if a species was not detected in the 'all' fraction above the threshold then this species was subsequently removed from respective 'IgG positive' and 'IgG negative' fractions. The 'IgAScores' (v.0.1.2)²⁵ R package was used to calculate IgG probability ratios using the 'igascores' function with method set to 'probratio', pseudocount 'c' set to $1 \ge 10^{-5}$ and 'scaleratio' set to TRUE.

$$probability \ ratio_{ij} = log2\left(\frac{\left(IgG_{ij}^{+} \times Fraction \ size_{j}^{IgG+}\right) + c}{\left(IgG_{ij}^{-} \times Fraction \ size_{j}^{IgG-}\right) + c}\right)$$

526 Alpha diversity

The diversity function from the 'vegan' R package (v.2.5-7)⁴⁶ was used to calculate Shannon indices and inverse Simpson indices. The rarefy function from 'vegan' (v.2.5-7)⁴⁶ was used to rarefy reads to the lowest sequencing depth. Observed species' richness was the number of species remaining following rarefaction.

531 *Beta diversity*

The vegdist function from 'vegan' $(v.2.5-7)^{46}$ was used to calculate Bray-Curtis indices on relative abundances. The metMDS function from 'vegan' $(v.2.5-7)^{46}$ was used to performed non-metric multidimensional scaling (NDMS) on Bray-Curtis indices.

535 Functional analysis

536 Gene families were identified using the HMP Unified Metabolic Analysis Network 3.0 (HUMAnN 3.0) package from the bioBakery suite^{47,48}. In all participants each gene family 537 was filtered by the following criteria: if a gene family was not present in the 'all' fraction the 538 539 reads per kilobase (RPK) were zeroed in the 'IgG positive' and 'IgG negative' fractions of 540 that participant. The humann_renorm_table utility script from HUMAnN 3.0 was used to 541 convert gene families from RPK to relative abundances. Community level classifications of gene families were used in downstream analysis. A cut off threshold of 1×10^{-6} was applied 542 543 to all samples.

To analyse gene families in the microbiome of severe ME/CFS patients compared with household controls the 'all' fraction was used. Gene families that were below the threshold in seven or more samples were discarded from downstream analysis. The clr

function from the 'compositions' R package (v 2.0-4) 49 was used to CLR transform the relative abundance of gene families. The pca function from the 'mixOmics' R package (v 6.18.1) 50 was used to perform principal component analysis (PCA) on gene families. Severe ME/CFS patients and their matched household controls were not treated as paired samples in this analysis.

To analyse gene families of IgG reactive microbes IgG probability ratios were calculated using the relative abundance of gene families in the 'IgG positive' fraction and the 'IgG negative' fraction as described earlier, with a pseudocount set to 6×10 . Gene families that did not have IgG probability ratios in all samples were discarded from downstream analysis. PCA was then performed as described previously.

557 Statistical analysis

Statistical analyses and graphical representations were performed in R using the following packages: 'ggplot2' (v3.4.0) ⁵¹, 'reshape2' (v1.4.4) ⁵², 'data.table' (v1.14) ⁵³, 'dplyr' (v1.1.0) ⁵⁴, 'ggpubr' (V0.5.0) ⁵⁵. Graphs were also made using GraphPad Prism 5.04. Prior to analysis data were log-transformed if there was evidence for non-normality. Pairwise comparisons between severe ME/CFS patients and their matched household controls were done using a two-tailed paired *t*-test. Correlations were assessed with Pearson (*r*) correlation test.

- 564 Common data elements for ME research
- 565 This study used the National Institute of Neurological Disorders and Stroke Common Data
- 566 Elements guidelines' for reporting microbiome/microorganisms biomarkers in ME/CFS
- 567 research (<u>http://www.commondataelements.ninds.nih.gov/</u>)⁵⁶.
- 568 Acknowledgements

569	We acknowledge East Coast Community Healthcare ME/CFS service and the CFS clinic at
570	Epsom and St Helier University Hospitals NHS Trust for their help recruiting patients, the
571	QIB Human Research Governance Committee (HRGC) for reviewing the HRA application
572	and all the research participants who generously shared their time. KAS was supported by a
573	PhD studentship jointly funded by Invest in ME Research (UK charity number 1153730) and
574	the University of East Anglia. The authors gratefully acknowledge the support of the
575	Biotechnology and Biological Sciences Research Council (BBSRC); The authors gratefully
576	acknowledge the support of the Biotechnology and Biological Sciences Research Council
577	(BBSRC); this research was supported by the BBSRC Institute Strategic Programme Grant
578	Gut Microbes and Health BB/R012490/1 and its constituent projects BBS/E/F/000PR10353
579	and BBS/E/F/000PR10355 (SRC). MD and GS were funded by the BBSRC Core Capability
580	Grant BB/CCG1860/1.

- 581 **Declaration of interest statement**
- 582 The authors report there are no competing interests to declare.
- 583 Data availability statement
- 584 The raw WMS data are available at the European Nucleotide Archive under study accession
- 585 PRJEB61661. (http://www.ebi.ac.uk/ena/broswer/view/PRJEB61661).

586 **References**

- Lim EJ, Son CG. Review of case definitions for myalgic encephalomyelitis/chronic
 fatigue syndrome (ME/CFS). J. Transl. Med. 2020;18:289. doi: 10.1186/s12967-02002455-0. PMID: 32727489.
- Pendergrast T, Brown A, Sunnquist M, Jantke R, Newton JL, Strand EB, Jason LA.
 Housebound versus nonhousebound patients with myalgic encephalomyelitis and
 chronic fatigue syndrome. Chronic Illn. 2016;12:292-307. doi:
 10.1177/1742395316644770. PMID: 27127189.
- Solution Chu L, Valencia IJ, Garvert DW, Montoya, JG. Onset Patterns and Course of Myalgic
 Encephalomyelitis/Chronic Fatigue Syndrome. Front Pediatr. 2019;7:12. doi:
 10.3389/fped.2019.00012. PMID: 30805319.
- Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and metaanalysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis
 (CFS/ME). J. Transl. Med. 2020;18:100. doi: 10.1186/s12967-020-02269-0. PMID:
 32093722.
- 5 Salari N, Khodayari Y, Hosseinian-Far A, Zarei H, Rasoulpoor S, Akbari H,
 Mohammadi M. Global prevalence of chronic fatigue syndrome among long COVID19 patients: A systematic review and meta-analysis. Biopsychosoc. Med. 2022;16:21.
 doi: 10.1186/s13030-022-00250-5. PMID: 36274177.
- 605 6 Missailidis D, Annesley SJ, Fisher, PR. Pathological Mechanisms Underlying
 606 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Diagnostics (Basel).
 607 2019;9:80. doi: 10.3390/diagnostics9030080. PMID: 31330791.
- Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with
 chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch.
 Intern. Med. 2000;160:221-227. doi: 10.1001/archinte.160.2.221. PMID: 10647761.

- 611 8 Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced
- 612 diversity and altered composition of the gut microbiome in individuals with myalgic 613 encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016;4:30. doi:
- 614 10.1186/s40168-016-0171-4. PMID: 27338587.
- Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG,
 Komaroff AL, Levine S, Montoya JG, et al. Fecal metagenomic profiles in subgroups
 of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome.
 2017;5:44. doi: 10.1186/s40168-017-0261-y. PMID: 28441964.
- Armstrong CW, McGregor NR, Lewis DP, Butt HL, Gooley PR. The association of
 fecal microbiota and fecal, blood serum and urine metabolites in myalgic
 encephalomyelitis/chronic fatigue syndrome. Metabolomics. 2016;13:8. doi:
 10.1007/s11306-016-1145-z.
- 623 11 Xiong R, Gunter C, Fleming E, Vernon SD, Bateman L, Unutma. Multi-'omics of gut 624 interactions microbiome-host in shortand long-term myalgic 625 encephalomyelitis/chronic fatigue syndrome patients. Cell Host Microbe. 2023;31:273-287.e275. doi: 10.1016/j.chom.2023.01.001. PMID: 36758521. 626
- 627 12 Guo C, Che X, Briese T, Ranjan A, Allicock O, Yates RA, Cheng A, March D, 628 Hornig M, Komaroff AL et al. Deficient butyrate-producing capacity in the gut 629 microbiome is associated with bacterial network disturbances and fatigue symptoms 630 in ME/CFS. Cell Host Microbe. 2023;31:288-304.e288. doi: 631 10.1016/j.chom.2023.01.004. PMID: 36758522.
- Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of
 enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of
 gram-negative enterobacteria in the etiology of CFS and for the presence of an

- 635 increased gut-intestinal permeability. J. Affect. Disord. 2007;99:237-240. doi:
 636 10.1016/j.jad.2006.08.021. PMID: 17007934.
- 637 14 Shukla SK, Cook D, Meyer J, Vernon SD, Le T, Clevidence D, Robertson CE,
 638 Schrodi SJ, Yale S, Frank DN. Changes in Gut and Plasma Microbiome following
 639 Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
 640 (ME/CFS). PLoS One. 2015;10:e0145453. doi: 10.1371/journal.pone.0145453.
 641 PMID: 26683192.
- Duchmann R, Neurath MF, Meyer zum Büschenfelde KH. Responses to self and nonself intestinal microflora in health and inflammatory bowel disease. Res. Immunol.
 1997;148:589-594. doi: 10.1016/s0923-2494(98)80154-5. PMID: 9588839.
- Harmsen HJ, Pouwels SD, Funke A, Bos NA, Dijkstra G. Crohn's disease patients
 have more IgG-binding fecal bacteria than controls. Clin. Vaccine Immunol.
 2012;19:515-521. doi:10.1128/cvi.05517-11. PMID: 22336288.
- Ruff WE, Greiling TM, Kriegel MA. Host-microbiota interactions in immunemediated diseases. Nat. Rev. Microbiol. 2020;18:521-538. doi: 10.1038/s41579-0200367-2. PMID: 32457482.
- Maes M, Ringel K, Kubera M, Anderson G, Morris G, Galecki P, Geffard M. In
 myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity
 against 5-HT is associated with immuno-inflammatory pathways and bacterial
 translocation. J. Affect. Disord. 2013;150:223-230. doi: 10.1016/j.jad.2013.03.029.
 PMID: 23664637.
- Quigley EMM. Gut bacteria in health and disease. Gastroenterol Hepatol (N Y).
 2013;9:560-569. PMID: 24729765.

- 65820Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, Function, and659Therapeutic Use of IgM Antibodies. Antibodies (Basel). 2020;9:53. doi:
- 660 10.3390/antib9040053. PMID: 33066119.
- de Sousa-Pereira P, Woof JM. IgA: Structure, Function, and Developability.
 Antibodies (Basel). 2019;8:57. doi: 10.3390/antib8040057. PMID: 31817406.
- Vogl T, Kalka IN, Klompus S, Leviatan S, Weinberger A, Segal E. Systemic antibody
 responses against human microbiota flagellins are overrepresented in chronic fatigue
 syndrome patients. Sci Adv. 2022;8:eabq2422. doi: 10.1126/sciadv.abq2422. PMID:
 36149952.
- Vogl T, Klompus S, Leviatan S, Kalka IN, Weinberger A, Wijmenga C, Fu J,
 Zhernakova A, Weersma RK, Segal E. Population-wide diversity and stability of
 serum antibody epitope repertoires against human microbiota. Nat. Med.
 2021;27:1442-1450. doi: 10.1038/s41591-021-01409-3. PMID: 34282338.
- Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L, Degnan PH,
 Hu J, Peter I, Zhang W, et al. Immunoglobulin A coating identifies colitogenic
 bacteria in inflammatory bowel disease. Cell. 2014;158:1000-1010. doi:
 10.1016/j.cell.2014.08.006. PMID: 25171403.
- Jackson MA, Pearson C, Ilott NE, Huus KE, Hegazy AN, Webber J, Finlay BB,
 Macpherson AJ, Powrie F, Lam LH. Accurate identification and quantification of
 commensal microbiota bound by host immunoglobulins. Microbiome. 2021;9:33.
 doi: 10.1186/s40168-020-00992-w. PMID: 33516266.
- Redondo-Useros N, Nova E, González-Zancada N, Díaz LE, Gómez-Martínez S,
 Marcos A. Microbiota and Lifestyle: A Special Focus on Diet. Nutrients.
 2020;12:1776. doi: 10.3390/nu12061776. PMID: 32549225.

- 682 27 Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen MAY, Bolte LA, Andreu-
- 683 Sánchez S, Chen L, Collij V, Hu S et al. Environmental factors shaping the gut
- 684 microbiome in a Dutch population. Nature. 2022;604:732-739. doi:10.1038/s41586-
- 685 022-04567-7. PMID: 35418674.
- Lupo GFD, Rocchetti G, Lucini L, Lorusso L, Manara E, Bertelli M, Puglisi E,
 Capelli E. Potential role of microbiome in Chronic Fatigue Syndrome/Myalgic
 Encephalomyelits (CFS/ME). Sci. Rep. 2021;11:7043. doi: 10.1038/s41598-02186425-6. PMID: 33782445.
- Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol.
 2016;16:626-638. doi:10.1038/nri.2016.90. PMID: 27546235.
- Milan-Mattos JC, Anibal FF, Perseguini NM, Minatel V, Rehder-Santos P, Castro
 CA, Vasilceac FA, Mattiello SM, Faccioli LH, Catai AM. Effects of natural aging and
 gender on pro-inflammatory markers. Braz J Med Biol Res. 2019;52:e8392. doi:
 10.1590/1414-431x20198392. PMID: 31411315.
- Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y. Host variables
 confound gut microbiota studies of human disease. Nature. 2020;587:448-454. doi:
 10.1038/s41586-020-2881-9. PMID: 33149306.
- Lax S, Smith DP, Hampton-Marcell J, Owens SM, Handley KM, Scott NM, Gibbons
 SM, Larsen P, Shogan BD, Weiss S, et al. Longitudinal analysis of microbial
 interaction between humans and the indoor environment. Science. 2014;345:10481052. doi: 10.1126/science.1254529. PMID: 25170151.
- Guenther S, Loebel M, Mooslechner AA, Knops M, Hanitsch LG, Grabowski P,
 Wittke K, Meisel C, Unterwalder N, Volk HD, et al. Frequent IgG subclass and
 mannose binding lectin deficiency in patients with chronic fatigue syndrome. Hum.
 Immunol. 2015;76:729-735. doi: 10.1016/j.humimm.2015.09.028. PMID: 26429318.

- Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME,
- Zareian N, Accardi G. Immunosenescence and Its Hallmarks: How to Oppose AgingStrategically? A Review of Potential Options for Therapeutic Intervention. Front.
- 710 Immunol. 2019;10:2247. doi: 10.3389/fimmu.2019.02247. PMID: 31608061.
- Eaton-Fitch N, du Preez S, Cabanas H, Staines D, Marshall-Gradisnik S. A systematic
 review of natural killer cells profile and cytotoxic function in myalgic
 encephalomyelitis/chronic fatigue syndrome. Syst Rev. 2019;8:279.
 doi:10.1186/s13643-019-1202-6. PMID: 31727160.
- Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L, Baxter A, Nathan
 N, Anderson W, Gordon E. Metabolic features of chronic fatigue syndrome. Proc.
 Natl. Acad. Sci. U. S. A. 2016;113:E5472-5480. doi: 10.1073/pnas.1607571113.
 PMID: 27573827.
- Morris G, Maes M, Berk M, Puri BK. Myalgic encephalomyelitis or chronic fatigue
 syndrome: how could the illness develop? Metab. Brain Dis. 2019;34:385-415. doi:
 10.1007/s11011-019-0388-6. PMID: 30758706.
- Baker R, Shaw EJ. Diagnosis and management of chronic fatigue syndrome or
 myalgic encephalomyelitis (or encephalopathy): summary of NICE guidance. BMJ.
 2007;335:446-448. doi: 10.1136/bmj.39302.509005.AE. PMID: 17762037.
- Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic
 fatigue syndrome: a comprehensive approach to its definition and study. International
 Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-9. doi:
 10.7326/0003-4819-121-12-199412150-00009. PMID: 7978722.
- 40 Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time.
 730 Scand J Gastroenterol. 1997;32:920-4. doi: 10.3109/00365529709011203. PMID:
 731 9299672.

- 41 Grüning B, Dale R, Sjödin A, Chapman BA, Rowe J, Tomkins-Tinch CH, Valieris R,
- Köster J; Bioconda Team. Bioconda: sustainable and comprehensive software
 distribution for the life sciences. Nat Methods. 2018;15:475-476. doi:
 10.1038/s41592-018-0046-7. PMID: 29967506.
- Telatin A, Fariselli P, Birolo G. SeqFu: A Suite of Utilities for the Robust and
 Reproducible Manipulation of Sequence Files. Bioengineering (Basel). 2021;8:59.
 doi: 10.3390/bioengineering8050059. PMID: 34066939.
- Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
 Bioinformatics. 2018;34:i884-i890. doi: 10.1093/bioinformatics/bty560. PMID: 30423086.
- Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2.
 Genome Biol. 2019;20:257. doi: 10.1186/s13059-019-1891-0. PMID: 31779668.
- Lu J, Breitwieser FP, Thielen P, Salzberg SL. Bracken: estimating species abundance
 in metagenomics data. PeerJ Computer Science. 2017;3:e104. doi: 10.7717/peerjcs.104
- Oksanen J, Simpson GL, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'Hara
 RB, Solymos P, Stevens MHH, Szoecs E, et al. _vegan: Community Ecology
 Package_. R package version v.2.6-4. 2022. <<u>https://CRAN.R-</u>
 project.org/package=vegan>.
- 47 Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan
 A, Manghi P, Scholz M, Thomas AM, et al. Integrating taxonomic, functional, and
 strain-level profiling of diverse microbial communities with bioBakery 3. Elife.
 2021;10:e65088. doi: 10.7554/eLife.65088. PMID: 33944776.

- 48 McIver LJ, Abu-Ali G, Franzosa EA, Schwager R, Morgan XC, Waldron L, Segata N,
- 756 Huttenhower C. bioBakery: a meta'omic analysis environment. Bioinformatics.
- 757 2018;34:1235-1237. doi: 10.1093/bioinformatics/btx754. PMID: 29194469.
- van den Boogaart KG, Tolosana-Delgado R, Bren M. _compositions: Compositional
- Data Analysis_. R package version 2.0-6. 2023. <<u>https://CRAN.R-</u>
 project.org/package=compositions>.
- 761 50 Rohart F, Gautier B, Singh A, Lê Cao KA. mixOmics: An R package for 'omics
 762 feature selection and multiple data integration. PLoS Comput Biol.
 763 2017;13:e1005752. doi: 10.1371/journal.pcbi.1005752. PMID: 29099853.
- 764 51 Wickham, H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer765 Verlag; 2016.
- Wickham, H. Reshaping Data with the reshape Package. J Stat Soft. 2007;21:1-20.
 doi: 10.18637/jss.v021.i12.
- Dowle M, Srinivasan A. _data.table: Extension of `data.frame`_. R package version
 1.14.6. 2022. <<u>https://CRAN.R-project.org/package=data.table></u>.
- 770 54 Wickham H, François R, Henry L, Müller K, Vaughan D. _dplyr: A Grammar of Data
- 771 Manipulation_. R package version 1.1.0. 2023. <<u>https://CRAN.R-</u>
 772 project.org/package=dplyr>.
- Alboukadel K. _ggpubr: 'ggplot2' Based Publication Ready Plots_. R package version
 0.6.0. 2023. <<u>https://CRAN.R-project.org/package=ggpubr</u>>.
- 775 56 Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National
- Institute of Neurological Disorders and Stroke Common Data Element Project approach and methods. Clin Trials. 2012;9:322-329. doi:
 10.1177/1740774512438980. PMID: 22371630.

780 Table 1. Severe ME/CFS clinical characteristics

	Participants affected (%)	Mean (SD)	Range
Age of ME/CFS onset (years)	-	25.0 (9.34)	12-38
Length of ME/CFS (years)	-	8.4 (6.83)	2-21
Symptoms			
Post exertional malaise	100	-	-
Non-restorative sleep	100	-	-
Headaches of a new onset, pattern and severity	80	-	-
Recurrent sore throat with enlarged glands in neck	40	-	-
Impaired concentration	100	-	-
Impaired memory	80	-	-
Joint pain	60	-	-
Muscle pain	80	-	-
Visual and/or auditory hypersensitivity	100	-	-
Irritable bowel syndrome	100	-	-
Questionnaire (maximum score)			
Shortened SF-36 (30) *	-	11.0 (1.73)	10-14
Chalder fatigue – physical (28) *	-	24.0 (3.67)	18-27
Chalder fatigue – mental (16) *	-	13.5 (1.12)	12-15
HADS – anxiety (21) *	-	7.8 (4.55)	3-15
HADS – depression (21) *	-	6.5 (5.50)	3-16

Self efficacy (60) **	-	12.0 (7.35)	3-21
Visual analogue (100) *	-	62.5 (36.31)	0-90
Epworth sleepiness (24) ***	-	7.5 (14)	1-14

* questionnaire completed by 4 patients ** questionnaire completed by 3 patients

*** questionnaire completed by 2 patients

781

Pair	Participant	Number of species detected per fraction			Proportion of species - IgG+	
		Only IgG- Only IgG+ Both IgG- and IgG+				
1	Patient	7	7	201	0.967	
	Control	23	7	173	0.887	
2	Patient	18	7	190	0.916	
	Control	21	6	202	0.908	
3	Patient	107	4	154	0.596	
	Control	14	12	145	0.918	
4	Patient	4	19	138	0.975	
	Control	29	6	168	0.857	
5	Patient	9	18	162	0.952	
	Control	15	31	206	0.940	

Table 2. Proportion of species detected that are recognised by serum IgG

784

786 SUPPLEMENTARY TABLE 1. The size of IgG positive and IgG negative fractions

collected during IgG-Seq. This data was used to calculation of IgG probability ratio scores.

Pair	Participant	Fraction sizes (%)	
	_	IgG+	IgG-
1	Patient	21.1	79.5
	Control	18.0	79.8
2	Patient	35.1	58.1
	Control	48.1	49.7
3	Patient	17.9	65.5
	Control	46.3	44.9
4	Patient	65.0	29.0
	Control	33.7	63.1
5	Patient	24.2	75.3
	Control	62.7	31.1

788

790	FIGURE 1. Stool consistency. (A) Analysis of stool consistency using the Bristol stool form
791	scale (BSFS) in severe ME/CFS patients (n=5) and matched household controls (n=5). P
792	values were calculated using a two-tailed paired t-test. (B) Water content in stool samples in
793	severe ME/CFS patients (n=5) and matched household controls (n=5). P values were
794	calculated using a two-tailed paired t-test.
795	
796	FIGURE 2. Concentration of IgA measured by ELISA in the stool of severe ME/CFS patients
797	(n=5) and matched household controls (n=5) for (A) microbe bound IgA, and (B) microbe
798	non-bound IgA. For both plots <i>p</i> values were calculated using a two-tailed paired <i>t</i> -test.
799	

800 FIGURE 3. Profiling stool IgA. (A) Overview of sample preparation for IgA-bound microbe

801 fluorescent activated cell sorting (FACS) analysis. (B) Representative flow cytometric

analysis of IgA-bound stool microbes. (C) Proportion of stool microbes bound by IgA in

severe ME/CFS patients (n=5) and matched household controls (n=5). P values were

calculated using a two-tailed paired t-test. (D) Analysis of IgA-bound microbial load in

severe ME/CFS patients (n=5) and matched household controls (n=5). P values were

806 calculated using a two-tailed paired t-test.

807

808 FIGURE 4. Serum IgG reactivity to autologous and heterologous stool microbes. (A)

809 Overview of assessment of IgG responses to indigenous (autologous) and foreign

810 (heterologous) stool microbes in severe ME/CFS patients and matched healthy household

811 controls. (B) Level of IgG in serum of severe ME/CFS patients (n=5) and household control

812 (n=5) binding to stool microbes from patient and control stool samples in vitro. (C) Levels of

813	IgG in serum of severe ME/CFS patients (n=5) and their matched household controls
814	quantified by ELISA (n=5). Two-tailed paired t-tests were used to calculate P values.

815

816	FIGURE 5. Quantifying stool microbes recognised by autologous serum IgG. (A) Overview
817	of sample preparation for IgG-bound microbe FACS analysis. (B) Representative analysis of
818	serum IgG binding to stool microbes. (C) Analysis of the proportion of stool microbes bound
819	by serum IgG in severe ME/CFS patients (n=5) and matched household controls (n=5). P
820	values were calculated using a two-tailed paired t-test.
821	
822	FIGURE 6. IgG-Seq. (A) IgG-Seq protocol used to determine taxa from stool samples

823 reactive to autologous serum IgG. (B) Representative flow cytometric dot plot showing IgG-824 Seq gating strategy based upon forward scatter (FSC) and back scatter (BSC) characteristics, 825 followed by discrimination of singlets from doublets. SYBR+ microbes were discriminated 826 from auto fluorescent debris and collected for profiling of all stool microbes. IgG positive 827 and IgG negative populations were sorted from SYBR+ events. (C) Pairwise comparisons of 828 observed richness of IgG positive and IgG negative microbes in severe ME/CFS patients 829 (n=5) and matched household controls (n=5). Analyses were performed at the species-level 830 reads rarefied to the lowest sequencing depth. P values were measured using two-tailed 831 paired t-tests. (D) Beta diversity of IgG positive species (filled shapes) and IgG negative 832 species (unfilled shapes) in severe ME/CFS patients (circles) and household controls 833 (squares). Beta-diversity was calculated using Bray-Curtis dissimilarity, presented on a non-834 metric multi-dimensional scaling (NMDS) plot.

835

836	FIGURE 7	. Probability of	of serum Ig	gG binding to	autologous	stool m	nicrobes t	from severe
				<u> </u>		~ ~ ~ ~ ~ ~ ~ ~ ~		

837 ME/CFS patients (n=5) and matched household controls (n=5). IgG probability ratios for

839

- 840 SUPPLEMENTARY FIGURE 1. Study participant recruitment pathway. Severe ME patients
- 841 were recruited from the CFS clinic at Epsom and St Helier University Hospitals (ESTH),
- 842 Carshalton, UK and the ME/CFS service at East Coast Community Healthcare Centre,

843 Lowestoft, UK.

844

645 SUFFLEWENTANT FIGURE 2. Stool inicioular load. Flow cytoinettic analysis of S	3 I BK
---	--------

846 Green+ microbial load in stool samples of severe ME/CFS patients (n=5) and matched

847 household controls (n=5).

848

849 SUPPLEMENTARY FIGURE 3. Stool microbiome profiling of severe ME/CFS patients

850 (n=5) and matched household controls (n=5). (A) Relative microbiome profiling (RMP) at

the genus-level. (B) quantitative microbiome profiling (QMP, cells per gram of faeces) at the

genus-level. (C) RMP at the species-level. (D) QMP at the species-level.

853

SUPPLEMENTARY FIGURE 4. Pairwise alpha- and beta-diversity comparisons of the stool
microbiomes of severe ME/CFS patients (n=5) and matched household controls (n=5).
Analyses were performed at the species-level on shotgun metagenomics data from SYBR+
stool microbes. (A) Alpha diversity measures of Shannon index, inverse Simpson index and
richness based on reads rarefied to the lowest sequencing depth. P values were measured

species detected in all participants stool samples.

859	using two-tailed paired t-tests. (B) Beta diversity of relative microbiome profiling (RMP) and
860	quantitative microbiome profiling (QMP, cells per gram faeces). Beta-diversity was
861	calculated using Bray-Curtis dissimilarity, presented on a non-metric multi-dimensional
862	scaling (NMDS) plot.
863	

864 SUPPLEMENTARY FIGURE 5. Functional composition of stool metagenomes from severe

ME/CFS patients (circles) (n=5) and matched household controls (squares) (n=5). Principal

component analysis (PCA) of the relative abundances of gene families. Pair numbers are

867 depicted on the graph but were not used in analysis.

868

869 SUPPLEMENTARY FIGURE 6. Functional profiling of stool microbes reactive with serum

870 IgG. Principal component analysis (PCA) of IgG probability ratios of gene families from the

stool microbiome in severe ME/CFS patients (circles) (n=5) and matched household controls

872 (squares) (n=5). Pair numbers are depicted on the graphs but were not used in analysis.



Α















status

- household control
 - severe ME/CFS

2

1

3 + 4 \boxtimes 5

Species